Clinical Nuclear Medicine · 2014 · 54 citations · 24 references
MedicineNuclear MedicineOncologyEndocrine OncologyRadionuclide TherapyTherapeutic Nuclear MedicineNeuroendocrine Tumor TherapyPeptide Receptor Radionuclide TherapyRadioiodine TherapyThyroid CancerThyroid ImagingThyroid ScintigraphyNeuroendocrine Tumor TracersPartial Response AssessmentRadiotracers Targeting Somatostatin ReceptorsSomatostatin Receptor ExpressionSomatostatin Receptor ScintigraphyThyroid Radionuclide UptakeThyroid Tumor ImagingTumor Shrinkage Assessment
BACKGROUND: Medullary thyroid cancer (MTC) is a rare but potentially life-threatening disease with limited therapeutic options. As a neuroendocrine tumor, MTC expresses somatostatin receptors, and therefore, somatostatin-labeled radiopharmaceuticals could be used to treat patients with MTC. OBJECTIVE: The aims of this study were to evaluate tumor shrinkage after Lu-DOTATATE treatment, to analyze the impact on quality of life as accessed by the SF-36 questionnaire, and to demonstrate a possible prognostic role for In-DTPA-octreotide uptake in patients with MTC. PATIENTS AND METHODS: Patients with progressive MTC underwent evaluation using In-DTPA-octreotide. Patients who demonstrated In-DTPA-octreotide uptake were treated with 4 cycles of 200 mCi of Lu-DOTATATE and were evaluated using CT scans over 8 to 12 months of treatment. RESULTS: Of the 16 patients initially enrolled, 9 (56.25%) had lesions that were observed in the In-DTPA-octreotide scans and were eligible for therapy with Lu-DOTATATE. Three patients had a partial response, 3 patients were classified as having stable disease and, 1 patient had a progressive disease. All responders indicated improvement in quality of life 6 to 12 months after therapy. CONCLUSIONS: Treatment with Lu-DOTATATE seems to be an alternative therapy for somatostatin receptor-positive tumors, with very mild adverse effects and quality-of-life improvement, at least during a short-term period. Further studies are needed to determine long-term benefits and to identify which patients are more likely to respond to this modality of therapy.
24
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Dik J. Kwekkeboom, Wouter W. de Herder, Boen L.R. Kam et al. · Journal of Clinical Oncology · 2008 · 1.4K citations · Full text
Medicine, Nuclear Medicine, Oncology +17
SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action
W. Bauer, U. Briner, W. Doepfner et al. · Life Sciences · 1982 · 1.3K citations
Cabozantinib in Progressive Medullary Thyroid Cancer
Rossella Elisei, Martin Schlumberger, Stefan Müller et al. · Journal of Clinical Oncology · 2013 · 1.2K citations · Full text
Medicine, Oncology, Pharmacology +14